Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor

Stefano De Santis, Andrea Pace, Loredana Bove, Francesco Cognetti, Francesca Properzi, Marco Fiore, Viviana Triaca, Antonella Savarese, Maria Domenica Simone, Bruno Jandolo, Luigi Manzione, Luigi Aloe

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of our study was to explore whether nerve growth factor (NGF) plays any role in the development of peripheral neuropathy induced by anticancer treatment. We measured the circulating NGF levels in 23 cancer patients before and after chemotherapy. We evaluated whether the development of peripheral neurotoxicity was associated with changes in basal NGF concentrations in patients studied with a comprehensive neurological and neurophysiological examination. The results of these studies showed that the circulating levels of NGF, which are about 20 pg/ml in plasma of controls, decrease during chemotherapy and in some cases completely disappeared after prolonged treatment with antitumor agents. The decrease in NGF levels seems to be correlated with the severity of neurotoxicity. These results clearly suggest that NGF might become a useful agent to prevent neuropathies induced by antineoplastic drugs and restore peripheral nerve dysfunction induced by these pharmacological compounds.

Original languageEnglish
Pages (from-to)90-95
Number of pages6
JournalClinical Cancer Research
Volume6
Issue number1
Publication statusPublished - Jan 2000

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor'. Together they form a unique fingerprint.

Cite this